Comparative Pharmacology
Head-to-head clinical analysis: LONITEN versus RAUWILOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LONITEN versus RAUWILOID.
LONITEN vs RAUWILOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arteries. It reduces peripheral vascular resistance and blood pressure by hyperpolarizing vascular smooth muscle cells via activation of ATP-sensitive potassium channels.
Rauwiloid (alseroxylon) is a rauwolfia alkaloid that depletes catecholamines and serotonin from postganglionic sympathetic nerve endings and the central nervous system by inhibiting vesicular monoamine transporter (VMAT). This leads to reduced peripheral vascular resistance and decreased sympathetic outflow, resulting in antihypertensive and antipsychotic effects.
10 mg orally twice daily, titrated to 40 mg twice daily for hypertension; for heart failure, start at 2.5-5 mg orally twice daily, max 20 mg twice daily.
2 mg orally twice daily, adjusted based on response; maximum 4 mg twice daily.
None Documented
None Documented
Terminal elimination half-life: 4.2 hours (range 3.5–5.5); clinically, half-life extends to 14–23 hours after chronic dosing due to drug accumulation.
Terminal elimination half-life is approximately 10–12 hours. Clinical context: Requires twice-daily dosing for sustained antihypertensive effect; steady-state achieved in 2–3 days.
Renal: 85% (12% unchanged, 73% as glucuronide conjugates); biliary/fecal: 3%
Primarily renal excretion of metabolites; ~60–80% of a dose is eliminated in urine as metabolites, with <1% as unchanged drug. Biliary/fecal excretion accounts for ~15%.
Category C
Category C
Antihypertensive
Antihypertensive